Theravance Biopharma (NASDAQ:TBPH) Downgraded by BidaskClub to Hold

BidaskClub cut shares of Theravance Biopharma (NASDAQ:TBPH) from a buy rating to a hold rating in a research note issued to investors on Friday morning, BidAskClub reports.

Several other equities analysts also recently weighed in on TBPH. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the company a buy rating in a research report on Friday, August 16th. Piper Jaffray Companies reiterated a buy rating on shares of Theravance Biopharma in a research report on Monday, September 9th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $44.25.

NASDAQ TBPH opened at $22.15 on Friday. The company has a market cap of $1.27 billion, a PE ratio of -5.55 and a beta of 1.72. The stock’s 50 day simple moving average is $21.52 and its 200-day simple moving average is $20.54. Theravance Biopharma has a 1-year low of $15.18 and a 1-year high of $35.48.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.50. The business had revenue of $26.15 million for the quarter, compared to the consensus estimate of $13.92 million. Theravance Biopharma had a negative return on equity of 2,631.15% and a negative net margin of 369.67%. Research analysts forecast that Theravance Biopharma will post -4.34 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Clearline Capital LP purchased a new position in Theravance Biopharma during the second quarter worth approximately $608,000. DekaBank Deutsche Girozentrale lifted its position in Theravance Biopharma by 64.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock worth $306,000 after buying an additional 7,500 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in Theravance Biopharma by 15.3% during the second quarter. Jacobs Levy Equity Management Inc. now owns 309,873 shares of the biopharmaceutical company’s stock worth $5,060,000 after buying an additional 41,060 shares in the last quarter. Fosun International Ltd lifted its position in Theravance Biopharma by 78.0% during the second quarter. Fosun International Ltd now owns 185,899 shares of the biopharmaceutical company’s stock worth $2,967,000 after buying an additional 81,434 shares in the last quarter. Finally, Bank of Montreal Can lifted its position in Theravance Biopharma by 28,276.0% during the second quarter. Bank of Montreal Can now owns 103,856 shares of the biopharmaceutical company’s stock worth $1,696,000 after buying an additional 103,490 shares in the last quarter. Hedge funds and other institutional investors own 84.16% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

See Also: What is the NASDAQ Stock Market?

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.